Cholecalciferol supplementation reduces soluble Klotho concentration in hemodialysis patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 6, 2013, Pages 277-281

  Hryszko, Tomasz ^a   Rydzewska Rosolowska, Alicja ^a   Gozdzikiewicz, Joanna ^a   Brzósko, Szymon ^a   Koc Zórawska, Ewa ^a   Zelazowska Rutkowska, Beata ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone metabolism; Cholecalciferol; Fibroblast growth factor 23; Hemodialysis; Klotho

Indexed keywords

25 HYDROXYVITAMIN D; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 23; JUVIT D 3; KLOTHO PROTEIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; FIBROBLAST GROWTH FACTOR; PEPTIDE;

ADULT; AGED; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS LINKING; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; OSSIFICATION; OSTEOLYSIS; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVENTION AND CONTROL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY; RENAL REPLACEMENT THERAPY; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CHOLECALCIFEROL; COLLAGEN TYPE I; DIETARY SUPPLEMENTS; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HUMANS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PEPTIDES; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY; YOUNG ADULT;

EID: 84882967886     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1768     Document Type: Article

References (28)

1. Stompór T, Olszewski A, Kierzkowska I. Can we prolong life of patients with advanced chronic kidney disease: What is the clinical evidence? Pol Arch Med Wewn. 2011; 121: 88-93.
2. Gutiérrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545-2552.
3. Janda K, Krzanowski M, Chowaniec E, et al. Osteoprotegerin as a marker of cardiovascular risk in peritoneal dialysis patients. Pol Arch Med Wewn. 2013: 123: 149-155.
4. Kanbay M, Nicoleta M, Selcoki Y, et al. Fibroblast growth factor 23 and fetuin a are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 1780-1786.
5. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592.
6. Arking DE, Krebsova A, Macek M, Sr., et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A. 2002; 99: 856-861.
7. Arking DE, Becker DM, Yanek LR, et al. Klotho allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet. 2003; 72: 1154-1161.
8. Arking DE, Atzmon G, Arking A, et al. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005; 96: 412-418.
9. Hryszko T, Brzosko S, Rydzewska-Rosolowska A, et al. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol. 2011; 44: 1479-1486.
10. Koizumi M, Komaba H, Nakanishi S, et al. Cinacalcet treatment and serum fgf23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2011; 27: 784-790.
11. Wesseling-Perry K, Pereira RC, Sahney S, et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011; 79: 112-119.
12. Hryszko T, Rydzewska-Rosolowska A, Brzosko S, et al. Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial. 2012; 16: 146-151.
13. Komaba H, Koizumi M, Tanaka H, et al. Effects of cinacalcet treatment on serum soluble klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012; 27: 1967-1969.
14. de Borst MH, Vervloet MG, ter Wee PM, Navis G. Cross talk between the renin-Angiotensin-Aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1603-1609.
15. Bednarek-Skublewska A, Smoleń A, Jaroszynski A, et al. Effects of vitamin D3 on selected biochemical parameters of nutritional status, inflammation, and cardiovascular disease in patients undergoing long-Term hemodialysis. Pol Arch Med Wewn. 2010; 120: 167-174.
16. Bindal ME, Taskapan H Hypovitaminosis D and insulin resistance in peritoneal dialysis patients. Int Urol Nephrol. 2011; 43: 527-534.
17. Mucsi I, Almási C, Deak G, et al. Serum 25(OH)-vitamin D levels and bone metabolism in patients on maintenance hemodialysis. Clin Nephrol. 2005; 64: 288-294.
18. Ambrus C, Almasi C, Berta K, et al. Vitamin D insufficiency and bone fractures in patients on maintenance hemodialysis. Int Urol Nephrol. 2011; 43: 475-482.
19. Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010; 31: 2253-2261.
20. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010; 5: 905-911.
21. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51.
22. Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001; 280: 1015-1020.
23. Komaba H, Goto S, Fujii H, et al. Depressed expression of klotho and fgf receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010; 77: 232-238.
24. Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich elisa for soluble alpha-klotho measurement: Age-dependent change of soluble alpha-klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010; 398: 513-518.
25. Sugiura H, Tsuchiya K, Nitta K. Circulating levels of soluble alpha-klotho in patients with chronic kidney disease. Clin Exp Nephrol. 2011; 15: 795-796.
26. Stubbs JR, Idiculla A, Slusser J, et al. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010; 21: 353-361.
27. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121: 4393-4408.
28. Kandula P, Dobre M, Schold JD, et al. Vitamin d supplementation in chronic kidney disease: A systematic review and meta-Analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011; 6: 50-62.